Related Experiment Video
Updated: Nov 3, 2025
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
1Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Abstract:
In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating IDH-mutant glioma. Lastly, we summarize the emerging therapeutic targets that can potentially be used in combination with TMZ.
Insights
Temozolomide (TMZ) shows promise for IDH-mutant gliomas but faces challenges like drug resistance and recurrence. New therapeutic targets are being explored for combination therapies to improve treatment outcomes.
Area of Science:
- Neuro-oncology
- Cancer Therapeutics
- Molecular Oncology
Background:
- IDH-mutant gliomas are a significant challenge in neuro-oncology.
- Temozolomide (TMZ) is a standard alkylating agent used in glioma treatment.
- Understanding TMZ's efficacy and limitations in IDH-mutant gliomas is crucial.
Purpose of the Study:
- To review the current use of temozolomide (TMZ) in treating IDH-mutant gliomas.
- To identify challenges in both clinical and preclinical settings for TMZ therapy.
- To explore potential novel therapeutic targets for combination strategies with TMZ.
Main Methods:
- Literature review of studies on temozolomide and IDH-mutant gliomas.
- Analysis of clinical data regarding drug resistance and tumor recurrence.
- Evaluation of in vitro models for preclinical research variability.
- Synthesis of information on emerging therapeutic targets.
Main Results:
- Temozolomide (TMZ) efficacy in IDH-mutant gliomas is hindered by clinical challenges such as drug resistance and tumor recurrence.
- Preclinical research using in vitro models presents variabilities that complicate drug development.
- Several emerging therapeutic targets show potential for enhancing TMZ treatment.
Conclusions:
- Temozolomide (TMZ) remains a key agent but requires strategies to overcome resistance in IDH-mutant gliomas.
- Addressing preclinical model variabilities is essential for advancing TMZ-based therapies.
- Combination therapies targeting novel pathways hold promise for improving outcomes in IDH-mutant glioma patients.
